# US 2013/0252279 A1 · Fixative and staining solutions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252279 A1
- Document ID: US20130252279A1
- Status: Published application
- Kind: A1
- Application number: 13/795,444
- Filed: 2013-03-12
- Published: 2013-09-26
- Earliest claimed: 2011-06-17
- Assignees: Constitution Medical, Inc.
- Applicants: Constitution Medical, Inc.
- Inventors: Daniel Lapen; Kerri Licari
- Web page: https://patentgrep.com/patent/US20130252279A1

## CPC

- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- Y10T 436/10: Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T 436/101666: Particle count or volume standard or control [e.g., platelet count standards, etc.]
- Y10T 436/108331: Preservative, buffer, anticoagulant or diluent
- Y10T 436/25: including sample preparation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The formulations, systems, and methods disclosed herein permit automated preparation of specimens (e.g., biological specimens) for examination. The disclosed formulations, systems, and methods provide fast, efficient, and highly uniform specimen processing using minimal quantities of fluids. The methods include at least a fixing phase for fixing a specimen to a substrate such as a microscope slide, a staining phase for staining the specimen, and a rinsing phase for rinsing the specimen. One or more of the fixing, staining, and rinsing phases include one or more agitation phases for distributing reagents evenly and uniformly across the specimen. The systems can be implemented as a standalone device or as a component in a larger system for preparing and examining specimens.

## Claims

### Claim 1

A cytological staining solution, comprising
Eosin Y;
a buffering agent;
a surfactant;
sodium chloride;
ethylene glycol; and
water.

### Claim 2 (depends on 1)

The cytological staining solution of claim 1, further comprising an antimicrobial agent.

### Claim 3 (depends on 2)

The cytological staining solution of claim 2, wherein the solution comprises from about 0.2 to about 50 ppm of the antimicrobial agent.

### Claim 4 (depends on 2)

The cytological staining solution of claim 2, wherein the antimicrobial agent is selected from the group consisting of benzalkonium chloride, 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one, ProClin<(R)>, azides, merthiolates, antibiotics, and any combination thereof.

### Claim 5 (depends on 2)

The cytological staining solution of claim 2, wherein the antimicrobial agent comprises 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one.

### Claim 6 (depends on 5)

The cytological staining solution of claim 5, wherein the antimicrobial agent is ProClin 300®.

### Claim 7 (depends on 1)

The cytological staining solution of claim 1, further comprising acetic acid.

### Claim 8 (depends on 1)

The cytological staining solution of claim 1, wherein the solution comprises from about 0.5 to about five percent by volume ethylene glycol.

### Claim 9 (depends on 1)

The cytological staining solution of claim 1, wherein the solution has a pH of from about 5 to about 8 and a buffering agent concentration of from about five to about 250 mM.

### Claim 10 (depends on 1)

The cytological staining solution of claim 1, wherein the buffering agent comprises bis-tris, phosphate, HEPES, MES, Tris, and any combination thereof.

### Claim 11 (depends on 10)

The cytological staining solution of claim 10, wherein the solution has a pH of from 5.8 to 6.2 and a bis-tris buffer concentration of from about five mM to about 250 mM.

### Claim 12 (depends on 1)

The cytological staining solution of claim 1, wherein the solution comprises from about 0.05 to about 0.5% of the surfactant.

### Claim 13 (depends on 12)

The cytological staining solution of claim 12, wherein the solution comprises from about 0.05% to about 0.3% by volume of the surfactant.

### Claim 14 (depends on 1)

The cytological staining solution of claim 1, wherein the surfactant is selected from the group consisting of non-ionic, cationic, anionic or zwitterionic surfactants.

### Claim 15 (depends on 14)

The cytological staining solution of claim 14, wherein the non-ionic surfactant is polysorbate 20.

### Claim 16 (depends on 15)

The cytological staining solution of claim 15, wherein the solution comprises from about 0.5 mL/L to about two mL/L of polysorbate 20.

### Claim 17 (depends on 1)

The cytological staining solution of claim 1, wherein the solution comprises from about one to about 20 g/L sodium chloride.

### Claim 18 (depends on 1)

The cytological staining solution of claim 1, wherein a 1:500 dilution of the solution in water has a UV absorbance of from about 0.1 to about one at a peak wavelength of from about 510 to about 530 nm.

### Claim 19 (depends on 1)

The cytological staining solution of claim 1, wherein the surfactant is non-ionic.

### Claim 20

A cytological staining solution, comprising
about 0.5 g/L to about 5.0 g/L Eosin Y;
about 5 mM to about 250 mM bis-tris buffer;
about 0.5 mL/L to about 2.0 mL/L polysorbate 20;
about one g/L to about 20 g/L sodium chloride;
about five mL/L to about 50 mL/L ethylene glycol;
about 0.2 ppm to about 50 ppm ProClin® 300;
acetic acid; and
water,
wherein the solution has a pH of from 5.8 to 6.2.
